Mina Kim Sells 17,986 Shares of Acelyrin, Inc. (NASDAQ:SLRN) Stock

Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Acelyrin Stock Performance

Shares of NASDAQ SLRN traded down $0.02 during mid-day trading on Friday, reaching $2.75. The company's stock had a trading volume of 1,392,082 shares, compared to its average volume of 1,209,203. The stock has a 50-day moving average of $2.29 and a two-hundred day moving average of $3.81. The stock has a market capitalization of $275.90 million, a P/E ratio of -1.12 and a beta of 1.25. Acelyrin, Inc. has a 1-year low of $1.85 and a 1-year high of $7.30.

Acelyrin (NASDAQ:SLRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07. Analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have issued reports on SLRN shares. Wells Fargo & Company decreased their price objective on shares of Acelyrin from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Wednesday, December 11th. HC Wainwright decreased their price target on shares of Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. Finally, Citigroup lowered their price objective on Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Acelyrin has an average rating of "Hold" and an average price target of $9.60.

Hedge Funds Weigh In On Acelyrin

Institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC acquired a new stake in Acelyrin during the fourth quarter worth $417,000. Stempoint Capital LP raised its stake in shares of Acelyrin by 29.4% in the fourth quarter. Stempoint Capital LP now owns 1,704,825 shares of the company's stock valued at $5,353,000 after acquiring an additional 386,971 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Acelyrin by 28.5% in the fourth quarter. ProShare Advisors LLC now owns 25,307 shares of the company's stock valued at $79,000 after purchasing an additional 5,617 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Acelyrin by 29.4% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 211,938 shares of the company's stock worth $665,000 after purchasing an additional 48,214 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Acelyrin by 53.4% during the 4th quarter. Deutsche Bank AG now owns 70,000 shares of the company's stock worth $220,000 after purchasing an additional 24,356 shares during the period. Hedge funds and other institutional investors own 87.31% of the company's stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.